181633-42-1

Basic information

• Product Name: 3-Pyridinamine, 6-[(2-methyl-3-pyridinyl)oxy]-
• Synonyms: 3-Pyridinamine, 6-[(2-methyl-3-pyridinyl)oxy]-;3-Amino-6-(2-methyl-3-pyridyloxy)pyridine
• CAS NO: 181633-42-1
• Molecular Formula: C₁₁H₁₁N₃O
• Molecular Weight: 201.22454
• Mol File: 181633-42-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Pyridinamine, 6-[(2-methyl-3-pyridinyl)oxy]-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Pyridinamine, 6-[(2-methyl-3-pyridinyl)oxy]-(181633-42-1)
• EPA Substance Registry System: 3-Pyridinamine, 6-[(2-methyl-3-pyridinyl)oxy]-(181633-42-1)

Safety Data

• Hazardous Substances Data: 181633-42-1(Hazardous Substances Data)

Upstream product

• 4548-45-2 2-chloro-5-nitropyridine 
• 1121-25-1 2-methyl-3-pyridinol 
• 200940-26-7 2-methyl-3-[(5-nitro-2-pyridinyl)oxy]pyridine 

Downstream Products

• 374555-24-5 [6-(2-Methylpyridin-3-yloxy)-pyridin-3-yl]-(5-phenyl-isoquinolin-1-yl)amine 
• 374555-40-5 (5-bromo-isoquinolin-1-yl)-[6-(2-methylpyridine-3-yloxy)pyridin-3-yl]amine 
• 602299-78-5 N-{6-[(2-methylpyridin-3-yl)oxy]pyridin-3-yl}-N'-(2-phenylethyl)urea 
• 602299-77-4 4-benzyl-N-{6-[(2-methylpyridin-3-yl)oxy]pyridin-3-yl}piperazine-1-carboxamide 
• 361550-55-2 (2E)-N-[6-(2-methyl-pyridin-3-yloxy)pyridin-3-yl]-3-[2-(trifluoromethyl)phenyl]-2-propenamide 
• 1051942-27-8 1H-benzimidazole-2-carboxylic acid [6-(2-methylpyridin-3-yloxy)-pyridin-3-yl]-amide 
• 200940-22-3 5-methyl-6-trifluoromethyl-2,3-dihydro-indole-1-carboxylic acid [6-(2-methyl-pyridin-3-yloxy)-pyridin-3-yl]-amide 
• 181632-25-7 SB 242084 
• 200940-27-8 phenyl N-[[2-(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamate 

Relevant articles and documents

Synthesis and Evaluation of Pyridyloxypyridyl Indole Carboxamides as Potential PET Imaging Agents for 5-HT2C Receptors

Nine pyridyloxypyridyl indole carboxamides were synthesized and displayed high affinities for 5-HT2C receptors and high selectivity over 5-HT2A and 5-HT2B. Among them, 6-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]1H-indole-3-carboxamide (8) exhibits the highest 5-HT2C binding affinity (Ki = 1.3 nM) and high selectivity over 5-HT2A (～1000 times) and 5-HT2B (～140 times). [11C]8 was synthesized by palladium-catalyzed coupling reaction between pinacolboranate 16 and [11C]CH3I with an average radiochemical yield of 27 ± 4% (n = 8, decay-corrected from end of [11C]CH3I synthesis). MicroPET imaging studies in rhesus monkeys showed regional uptake of [11C]8 in the choroid plexus, whereas the bindings in all other brain regions were low. The specific binding in the choroid plexus was confirmed by administration of a blocking dose of 0.1 mg/kg of the 5-HT2C antagonist SB-242084.

Preparation method of indoline compound

The invention discloses a preparation of indoline compound expressed by the following general formula 1; the method successfully passes through for step reactions by applying iodine monochloride, acetenyl trimethyl silane and other reaction reagents, and obtains 6-chlorine-5-methyl indoline. Relative to the prior art, the synthetic method of the indoline derivative reduces the reaction step while improves the reaction yield. Moreover, the reaction condition is gentle, and easy to control; the method is good for large-scale industrial production.

Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists

Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT2c receptors, act selectively on the 5-HT2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT2c receptors.